Literature DB >> 998703

The prognostic value of HLA-B12 and HLA-B7 antigens in patients with increased intraocular pressure.

D H Shin, B Becker.   

Abstract

The presence of the histocompatibility antigens HLA-B12 or HLA-B7 in 76 patients with increased intraocular pressure and a GG response to topical corticosteroids (intraocular pressure over 31 mm Hg after six weeks of topical 0.1% dexamethasone eyedrops, four times daily) correlated with the development of glaucomatous visual field loss. In close agreement with prevalences in patients with primary open-angle glaucoma, 14 (88%) of the 16 patients with increased intraocular pressure and a GG response who developed glaucomatous visual field loss had either HLA-B12 or B7 antigens. Fourteen (41%) of 34 patients with increased intraocular pressure and a GG response who had B12 or B7 antigens developed glaucomatous visual field loss but only two (5%) of 42 similar patients without either antigen had visual field loss. Other factors such as the initial intraocular pressure, the horizontal cup/disk ratio, and family history of glaucoma proved less valuable as prognostic indicators in this series.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 998703     DOI: 10.1016/0002-9394(76)90063-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  HLA antigens-risk factors for primary open-angle glaucoma?

Authors:  W R Mayr; G Grabner
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1978-09-11

2.  HLA antigens in glaucoma and ocular hypertension.

Authors:  R David; G Maier; I Baumgarten; C Abrahams
Journal:  Br J Ophthalmol       Date:  1979-05       Impact factor: 4.638

3.  Ocular complications of systemic steroid after renal transplantation and their association with HLA.

Authors:  H P Adhikary; R A Sells; P K Basu
Journal:  Br J Ophthalmol       Date:  1982-05       Impact factor: 4.638

4.  Ocular hypertension.

Authors: 
Journal:  Br Med J       Date:  1978-05-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.